孟鲁司特对中重度稳定期慢性阻塞性肺疾病的临床疗效
|
摘要
目的:研究孟鲁司特对中重度稳定期慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)的临床治疗效果。方法:选取选取2015年1月-2017年12月本院收治的60例中重度稳定期COPD患者临床资料进行分析,按照随机对数字表法分成对照组与观察组,每组30例。对照组给予信必可都保进行治疗,观察组在对照组治疗基础上增加孟鲁司特治疗,比较两组治疗效果。结果:观察组FEV_1、FEV_1%、FEV_1/FVC明显优于对照组,观察组呼吸困难和6-MWD评分明显优于对照组,差异均有统计学意义(P<0.05)。观察组不良反应发生率10.00%与对照组6.67%比较,差异无统计学意义(P>0.05)。结论:中重度稳定期COPD患者在常规治疗时联合孟鲁司特,疗效更为显著,值得推广应用。
Objective:To study the clinical effect of Montelukast on COPD in moderate-severe stable period.Method:A total of 60 patients with moderate-severe stable period COPD in our hospital from January 2015 to December 2017 were randomly divided into control group and observation group according to table of random numbers,30 patients in each group.The control group was treated with Symbicort,and observation group was treated with Montelukast on the basis of the control group.The treatment effects were compared between the two groups.Result:After treatment,the FEV_1,FEV_1% and FEV_1/FVC of the observation group were significantly better than those of the control group,the dyspnea and 6-MWD scores of the observation group were significantly better than those of the control group,the differences were statistically significant(P<0.05).There was no significant difference of incidence of adverse reactions between the observation group 10.00% and the control group 6.67%(P>0.05).Conclusion:The effect of conventional treatment combined with Montelukast is significant in patients with moderate-severe stable period COPD,it is worth promoting the application.
Objective:To study the clinical effect of Montelukast on COPD in moderate-severe stable period.Method:A total of 60 patients with moderate-severe stable period COPD in our hospital from January 2015 to December 2017 were randomly divided into control group and observation group according to table of random numbers,30 patients in each group.The control group was treated with Symbicort,and observation group was treated with Montelukast on the basis of the control group.The treatment effects were compared between the two groups.Result:After treatment,the FEV_1,FEV_1% and FEV_1/FVC of the observation group were significantly better than those of the control group,the dyspnea and 6-MWD scores of the observation group were significantly better than those of the control group,the differences were statistically significant(P<0.05).There was no significant difference of incidence of adverse reactions between the observation group 10.00% and the control group 6.67%(P>0.05).Conclusion:The effect of conventional treatment combined with Montelukast is significant in patients with moderate-severe stable period COPD,it is worth promoting the application.
引文
[1]汤森,闫静,徐文喜.孟鲁司特治疗慢性阻塞性肺疾病急性加重期60例的疗效观察[J/OL].中国医学前沿杂志(电子版),2014,6(3):75-77.
[2]郝月琴,孙书芳,孙岩,等.孟鲁司特对AECOPD的疗效及对肺动脉高压的影响[J].临床肺科杂志,2012,10(17):1806-1807.
[3]刘海玲,胡苏萍,聂汉祥,等.中重度稳定期慢性阻塞性肺疾病患者尿白三烯E4测定及临床意义[J].医学研究杂志,2017,46(2):119-122.
[4]Matsuse H,Hirose H,Tsuchida T,et al.Effects of respiratory syncytial virus ifecton on dendritic cells and cysteinyl leukotrienes in lung tissures of murine model of asthma[J].Allergol Int,2007,56(2):165-169.
[5]金烨,戴莉莉,陈晓红,等.白三烯受体拮抗剂治疗慢阻肺继发肺间质纤维化的临床疗效观察[J].临床肺科杂志,2013,18(6):1001-1003.
[6]郭小青,姜妤,陈曦,等.西地那非联合孟鲁司特钠用于慢性阻塞性肺疾病合并肺动脉高压的效果观察[J].河北医药,2017,39(21):3290-3296.
[7]袁平,吴国斌,刘欣欣.噻托溴铵联合孟鲁司特钠治疗慢性阻塞性肺疾病患者的疗效分析[J].抗感染药学,2016,13(3):586-589.
[8]中华医学会呼吸病学会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-266.
[9]严郁,苏娜,刘可欣,等.国内人群应用孟鲁司特钠治疗慢性阻塞性肺疾病的系统评价[J].中国药师,2013,16(10):1562-1565.
[10]巩增锋,张文强,苏筠霞,等.孟鲁司特治疗重度稳定期COPD的临床观察[J].甘肃医药,2013,32(6):406-408.
[11]肖建,杜春玲.慢性阻塞性肺疾病病因及发病机制研究进展[J].中国老年学杂志,2014,34(11):3191-3194.
[12]李佳.慢性阻塞性肺疾病的临床治疗进展[J].中国医学创新,2015,12(9):144-146.
[13]向左娟,孙宏斌.慢性阻塞性肺疾病的发病机制和临床药物研究进展[J].药学与临床研究,2013,21(1):47-56.
[14]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17.
[15]崔丹萍,蔡露西,周炜,等.孟鲁司特钠治疗中重度AECOPD的临床观察[J].中国现代药物应用,2012,6(2):85-86.
[16]李威,闫芳,王晶.口服孟鲁司特钠治疗慢性阻塞性肺疾病急性加重期疗效及安全性的Meta分析[J/OL].中华临床医师杂志:电子版,2015,9(9):151-153.
[17]李强,范洪峰,徐晓飞.孟鲁司特钠治疗急性加重期慢性阻塞性肺疾病疗效分析与评价[J].临床合理用药,2011,4(9C):24-25.
[18]熊小敏,吴鹏.布地奈德福莫特罗粉吸入剂联合孟鲁司特钠对慢性阻塞性肺疾病稳定期患者肺弥散功能的影响[J].医学综述,2016,22(24):4982-4985.
[19]李强,邹小新,饶常红.孟鲁司特联合噻托溴铵治疗慢性阻塞性肺疾病疗效的研究[J].重庆医学,2013,42(19):2278-2280.
[20]陈焕珍,戢秋明,李兰,等.孟鲁司特对中重度稳定期慢性阻塞性肺疾病的临床疗效及白三烯E4的作用研究[J].现代中西医结合杂志,2016,25(24):2675-2678.
[2]郝月琴,孙书芳,孙岩,等.孟鲁司特对AECOPD的疗效及对肺动脉高压的影响[J].临床肺科杂志,2012,10(17):1806-1807.
[3]刘海玲,胡苏萍,聂汉祥,等.中重度稳定期慢性阻塞性肺疾病患者尿白三烯E4测定及临床意义[J].医学研究杂志,2017,46(2):119-122.
[4]Matsuse H,Hirose H,Tsuchida T,et al.Effects of respiratory syncytial virus ifecton on dendritic cells and cysteinyl leukotrienes in lung tissures of murine model of asthma[J].Allergol Int,2007,56(2):165-169.
[5]金烨,戴莉莉,陈晓红,等.白三烯受体拮抗剂治疗慢阻肺继发肺间质纤维化的临床疗效观察[J].临床肺科杂志,2013,18(6):1001-1003.
[6]郭小青,姜妤,陈曦,等.西地那非联合孟鲁司特钠用于慢性阻塞性肺疾病合并肺动脉高压的效果观察[J].河北医药,2017,39(21):3290-3296.
[7]袁平,吴国斌,刘欣欣.噻托溴铵联合孟鲁司特钠治疗慢性阻塞性肺疾病患者的疗效分析[J].抗感染药学,2016,13(3):586-589.
[8]中华医学会呼吸病学会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-266.
[9]严郁,苏娜,刘可欣,等.国内人群应用孟鲁司特钠治疗慢性阻塞性肺疾病的系统评价[J].中国药师,2013,16(10):1562-1565.
[10]巩增锋,张文强,苏筠霞,等.孟鲁司特治疗重度稳定期COPD的临床观察[J].甘肃医药,2013,32(6):406-408.
[11]肖建,杜春玲.慢性阻塞性肺疾病病因及发病机制研究进展[J].中国老年学杂志,2014,34(11):3191-3194.
[12]李佳.慢性阻塞性肺疾病的临床治疗进展[J].中国医学创新,2015,12(9):144-146.
[13]向左娟,孙宏斌.慢性阻塞性肺疾病的发病机制和临床药物研究进展[J].药学与临床研究,2013,21(1):47-56.
[14]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17.
[15]崔丹萍,蔡露西,周炜,等.孟鲁司特钠治疗中重度AECOPD的临床观察[J].中国现代药物应用,2012,6(2):85-86.
[16]李威,闫芳,王晶.口服孟鲁司特钠治疗慢性阻塞性肺疾病急性加重期疗效及安全性的Meta分析[J/OL].中华临床医师杂志:电子版,2015,9(9):151-153.
[17]李强,范洪峰,徐晓飞.孟鲁司特钠治疗急性加重期慢性阻塞性肺疾病疗效分析与评价[J].临床合理用药,2011,4(9C):24-25.
[18]熊小敏,吴鹏.布地奈德福莫特罗粉吸入剂联合孟鲁司特钠对慢性阻塞性肺疾病稳定期患者肺弥散功能的影响[J].医学综述,2016,22(24):4982-4985.
[19]李强,邹小新,饶常红.孟鲁司特联合噻托溴铵治疗慢性阻塞性肺疾病疗效的研究[J].重庆医学,2013,42(19):2278-2280.
[20]陈焕珍,戢秋明,李兰,等.孟鲁司特对中重度稳定期慢性阻塞性肺疾病的临床疗效及白三烯E4的作用研究[J].现代中西医结合杂志,2016,25(24):2675-2678.